Anticoagulation in continuous renal replacement therapy

Current Opinion in Nephrology and Hypertension

Volumn 8, Issue 6, 1999, Pages 701-707

  Abramson, Stuart ^a   Niles, John L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; PROTAMINE;

ACUTE KIDNEY FAILURE; ANTICOAGULATION; ARTICLE; BLEEDING; EXTRACORPOREAL CIRCULATION; FILTER; HEMODIALYSIS; HUMAN; PRIORITY JOURNAL;

ANTICOAGULANTS; CITRATES; EPOPROSTENOL; HEMOFILTRATION; HEPARIN; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0033392211     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199911000-00009     Document Type: Article

References (41)

1. 1 Webb AR, Mythen MG, Jacobson D, Mackie IJ. Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation. Intens Care Med 1995; 21:84-93.
2. 2 Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous venovenous hemofiltration: a retrospective study. Am J Kidney Dis 1994; 24:806-812.
3. 3 Kaplan AA, Longnecker RE, Folkert VW. Continuous arteriovenous hemofiltration. A report of six months' experience. Ann Intern Med 1984; 100:358-367.
4. 4 Schneider NS, Geronemus RP. Continuous arteriovenous hemodialysis. Kidney Int 1988; 24 (suppl):S159-S162.
5. 5 Lauer A, Saccaggi A, Ronco C, Belledonne M, Glabman S, Bosch JP. Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics. Ann Intern Med 1983; 99:455-460.
6. 6 Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intens Care Med 1996; 22:1261-1264.
7. 7 van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7:145-150.
8. 8 Gretz N, Quintel M, Ragaller M, Odenwalder W, Bender HJ, Rohmeiss P, et al. Low-dose heparinization for anticoagulation in intensive care patients on continuous hemofiltration. Contrib Nephrol 1995; 116:130-135.
9. 9 Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intens Care Med 1993; 19:329-332.
10. 10 Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at high risk of bleeding. Kidney Int 1993; 41 (suppl):S237-S244.
11. 11 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95:315-328.
12. 12 Swartz RD. Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 1981; 28:65-69.
13. 13 Ronco C, Brendolan A, Bragantini L, Chiaramonte S, Feriani M, Fabris A, et al. Continuous arterio-venous haemofiltration. Contrib Nephrol 1985; 48:70-90.
14. 14 Bastien O, French P, Paulus S, Filley S, Berruyer M, Dechavanne M, et al. Antithrombin III deficiency during continuous venovenous hemodialysis. Contrib Nephrol 1995; 116:154-158.
15. 15 Langley PG, Keays R, Hughes RD, Forbes A, Delvos U, Williams R. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 1991; 14:251-256.
16. 16 Kaplan AA. Predilution versus postdilution for continuous arteriovenous hemofiltration. ASAIO Trans 1985; 31:28-32.
17. 17 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335.
18. 18 Ballard J. Anticoagulant-induced thrombosis. JAMA 1999; 282:310-312. This is a good review of heparin-induced thrombocypenia.
19. 19 Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. ASAIO Trans 1966; 12:207-209 .
20. 20 Horrow JC. Protamine: a review of its toxicity. Anesth Analg 1985; 64:348-3 61.
21. 21 Kaplan AA, Petrillo R. Regional heparinization for continuous arterio-venous hemofiltration (CAVH). ASAIO Trans 1987; 33:312-315.
22. 22 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688-698.
23. 23 Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33:890-896.
24. 24 Schrader J, Stibbe W, Kandt M, Warneke G, Armstrong V, Muller HJ, et al. Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients. ASAIO Trans 1990; 36:28-32.
25. 25 Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM. Anticoagulation with low molecular weight heparin (Fragmin) during continuous hemodialysis in the intensive care unit. Artif Org 1993; 17:717-720.
26. 26 Vane JR. The road to prostacyclin. Adv Prostaglandin Thromboxane Leukotriene Res 1985; 15:11-19.
27. 27 Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980; 2:219-222.
28. 28 Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304:934-939.
29. 29 Turney JH, Weston MJ. Dialysis without anticoagulants. Lancet 1981; 2:693.
30. 30 Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994; 22:1774-1781.
31. 31 Canaud B, Mion C, Arujo A, N'Guyen QV, Paleyrac G, Hemmendinger S, et al. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration. Nephron 1988; 48:206-212.
32. 32 Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66:431-437.
33. 33 Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38:976-981.
34. 34 Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 1999; 55:1991-1997. This paper describes a simple method for performing citrate anticoagulation in CRRT.
35. 35 Flanigan MJ, Von Brecht J, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis 1987; 9:147-153.
36. 36 Ashton DN, Mehta RL, Ward DM, McDonald BR, Aguilar MM. Recent advances in continuous renal replacement therapy: citrate anticoagulated continuous arteriovenous hemodialysis. Anna J 1993; 18:263-267, 329.
37. 37 Kirschbaum B, Galishoff M, Reines HD. Lactic acidosis treated with continuous hemodiafiltration and regional citrate anticoagulation. Crit Care Med 1992; 20:349-353.
38. 38 van Wyk V, Badenhorst PN, Luus HG, Kotze HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48:1338-1343.
39. 39 van Wyk V, Badenhorst PN, Kotze HF. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis. Clin Nephrol 1997; 48:381-387.
40. 40 Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991; 93:215-217.
41. 41 Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 1993; 23:135-141.